Navigation Links
Thoratec Announces Appointment of William A. Hawkins to Board of Directors
Date:12/16/2011

PLEASANTON, Calif., Dec. 16, 2011 /PRNewswire/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced the appointment of William A. Hawkins to its board of directors. 

"Bill brings tremendous skill, leadership, and experience to the Thoratec team, and we are delighted to add him to our board of directors," said Neil F. Dimick, Chairman of Thoratec's board of directors.  Gary F. Burbach, President and CEO, added, "Bill has been a leader in the healthcare industry for over three decades.  We are confident that his industry knowledge, strategic insight, and depth of experience, spanning from technology innovation to market development to broader healthcare policy, will be of great value to Thoratec."

Hawkins currently serves as President and Chief Executive Officer of Immucor, Inc. and as a Senior Advisor to TPG Capital.  Previously, he held a number of senior executive positions at Medtronic, Inc., including the role of Chairman and Chief Executive Officer.  Prior to Medtronic, Hawkins was the Chief Executive Officer of Novoste Corporation and held leadership positions at American Home Products, Eli Lilly, Johnson & Johnson, and Guidant.  Additionally, he has served on a number of corporate and non-profit boards of directors.

"I am excited to join the Thoratec board," said Mr. Hawkins.  "Thoratec has a rich history of innovation and leadership in the mechanical circulatory support industry, and I look forward to participating in the company's mission of driving greater adoption of its therapies, in order to deliver meaningful benefits to patients worldwide."

Mr. Hawkins's appointment will be effective as of January 1, 2012.  His appointment brings the number of the company's directors to nine.

Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate LVAS and Thoratec VAD, with more than 18,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and distributes the CentriMag® and PediMag® / PediVAS® product lines. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web site at http://www.thoratec.com.

Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation and IVAD is a trademark of Thoratec Corporation. CentriMag and PediMag are registered trademarks of Thoratec LLC, and PediVAS is a registered trademark of Thoratec Switzerland GmbH.

Many of the preceding paragraphs, particularly but not exclusively those addressing future performance, contain forward-looking statements within the meaning of Sections 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements can be identified by the words, "believes," "views," "expects," "plans," "projects," "hopes," "could," "will," and other similar words. Actual results, events or performance could differ materially from these forward-looking statements based on a variety of factors, many of which are beyond Thoratec's control. Therefore, readers are cautioned not to put undue reliance on these statements. Investors are cautioned that all such statements involve risks and uncertainties. Forward-looking statements contained in this press release should be considered in light of these factors and those factors discussed from time to time in Thoratec's public reports filed with the Securities and Exchange Commission, such as those discussed under the heading, "Risk Factors," in Thoratec's most recent annual report on Form 10-K and as may be updated in subsequent SEC filings. These forward-looking statements speak only as of the date hereof. Thoratec undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.

 


'/>"/>
SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009
5. Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology
6. Thoratec Schedules Fiscal 2009 Year-End Conference Call, Webcast
7. Thoratec Presentation at Canaccord Adams Conference to be Webcast
8. Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
9. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
10. Thoratec Presentation at Piper Jaffray Conference to be Webcast
11. Thoratec Presentation at Raymond James Conference to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... NEW YORK , January 24, 2017 ... of the fastest growing industries in the United ... for medicinal use in 2016. In addition, Proposition 64, the ... 57.13% for and 42.87% against on November 8, 2016. This ... are allowed to use and to grow a certain amount ...
(Date:1/24/2017)... , January 24, 2017 ... value of USD 3.8 billion by 2025, according to ... market growth can be attributed to the rising initiatives ... early diagnosis of micro calcifications in breast tissue. Some ... CDC, and Breast Cancer Organization are promoting the early ...
(Date:1/24/2017)... -- Aptuit, LLC, hat heute den Beginn ... General Hospital (MGH) unter Leitung von Dr. Laurence ... und Validierung neuartiger Targets in gramnegativen Bakterien.  Aptuit erhofft ... Antibiotika bei der Behandlung schwerer Infektionen entgegenwirken können. ... ...
Breaking Medicine Technology:
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... The ... MSC Cruises as part of the line’s 4th Annual MSC True Partnerships’ Awards. ... performing North American travel partners for the year based on overall business growth in ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... announced that it has officially formed a distribution partnership with Byers Scientific ... industrial odor management industry. , Through the agreement, OMI Industries formulated a special ...
(Date:1/24/2017)... ... January 24, 2017 , ... Providing solutions to critical ... from the Frank Hawkins Kenan Institute of Private Enterprise at the ... policy makers identified concrete solutions at the “What’s Next, America?” conference at the ...
(Date:1/24/2017)... ... January 24, 2017 , ... Date aired: January 23, ... Kleyne, the nation’s foremost water advocate and host of the nationally syndicated The ... Voice America, once again welcomed one of her favorite guests and colleagues, Dr. ...
(Date:1/24/2017)... ... ... “Speaking With God’s Voice”: a resolute and spirited call for anointed preaching ... A. Miraglia, a born-again believer, who spent his years teaching high school and Sunday-school, ... “There is little doubt that God Himself prepared me for this study, and God’s ...
Breaking Medicine News(10 mins):